Efficacy of Camrelizumab in Advanced Non-Small-Cell Lung Cancer and Prognostic Analysis of Different PET/CT Features

OBJECTIVE: To evaluate the efficacy of the PD-1 inhibitor camrelizumab plus chemotherapy in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) and the prognostic differences of patients with different PET/CT features. METHODS: Between December 2018 and October 2020, 100 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Jinhai, Li, Chunying, Han, Yu, Xing, Yu, Zhan, Yingying, Zuo, Chao, Ren, Xinyue, Xing, Rongge, Zhang, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975645/
https://www.ncbi.nlm.nih.gov/pubmed/35368889
http://dx.doi.org/10.1155/2022/9942918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975645/
https://www.ncbi.nlm.nih.gov/pubmed/35368889
http://dx.doi.org/10.1155/2022/9942918

Ejemplares similares